| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Immunology |
Departments of Immunohematology and Blood Transfusion [S. Z., M. P. M. V., S. C. F. M., J. A. H., M. E. O., R. P. M. S., K. L. M. C. F., H. W. N., F. O., S. H. v. d. B., R. O., C. J. M. M.] and Surgery [S. Z.], Leiden University Medical Center, 2333 ZA Leiden, the Netherlands
Overexpression of p53 is found in
50% of human cancers, making it an attractive target antigen for immunotherapy of cancer. Research in this area has thus far primarily focused on p53-specific CTLs. Although these CTLs were shown to be highly effective against p53-overexpressing tumors in vivo, immunological tolerance seems to strongly restrict the spectrum of the p53-specific CTL repertoire in p53+/+ subjects. In view of the emerging role of CD4+ Th (Th) cells in the antitumor response, we investigated the specificity and antitumor efficacy of the p53-specific Th response in mice. Our data show that high affinity Th cells against the naturally processed epitope p53108122 can be elicited in both p53-/- and p53+/+ mice, indicating that the p53-specific T-cell response is not affected by tolerance at the Th level. Furthermore, p53108122-specific Th cells were effective in enabling p53-specific CTLs to control the growth of p53-overexpressing tumors in vivo. Therefore, exploitation of the p53-specific Th response appears to be a highly useful aspect of immunotherapeutic strategies against cancers.
This article has been cited by other articles:
![]() |
F. M. Speetjens, P. J.K. Kuppen, M. J.P. Welters, F. Essahsah, A. M. E.G. Voet van den Brink, M. G. K. Lantrua, A. R. P.M. Valentijn, J. Oostendorp, L. M. Fathers, H. W. Nijman, et al. Induction of p53-Specific Immunity by a p53 Synthetic Long Peptide Vaccine in Patients Treated for Metastatic Colorectal Cancer Clin. Cancer Res., February 1, 2009; 15(3): 1086 - 1095. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Lauwen, S. Zwaveling, L. de Quartel, S. C. Ferreira Mota, J. A.C. Grashorn, C. J.M. Melief, S. H. van der Burg, and R. Offringa Self-Tolerance Does Not Restrict the CD4+ T-Helper Response against the p53 Tumor Antigen Cancer Res., February 1, 2008; 68(3): 893 - 900. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Erfurt, Z. Sun, I. Haendle, B. Schuler-Thurner, C. Heirman, K. Thielemans, P. van der Bruggen, G. Schuler, and E. S. Schultz Tumor-Reactive CD4+ T Cell Responses to the Melanoma-Associated Chondroitin Sulphate Proteoglycan in Melanoma Patients and Healthy Individuals in the Absence of Autoimmunity J. Immunol., June 15, 2007; 178(12): 7703 - 7709. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Antonia, N. Mirza, I. Fricke, A. Chiappori, P. Thompson, N. Williams, G. Bepler, G. Simon, W. Janssen, J.-H. Lee, et al. Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer Clin. Cancer Res., February 1, 2006; 12(3): 878 - 887. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Wu, A. Ootani, R. Iwakiri, Y. Sakata, T. Fujise, S. Amemori, F. Yokoyama, S. Tsunada, S. Toda, and K. Fujimoto T Cell Deficiency Leads to Liver Carcinogenesis in Azoxymethane-Treated Rats Exp Biol Med, January 1, 2006; 231(1): 91 - 98. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Kudo-Saito, J. Schlom, K. Camphausen, C. N. Coleman, and J. W. Hodge The Requirement of Multimodal Therapy (Vaccine, Local Tumor Radiation, and Reduction of Suppressor Cells) to Eliminate Established Tumors Clin. Cancer Res., June 15, 2005; 11(12): 4533 - 4544. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Chakraborty, S. I. Abrams, C. N. Coleman, K. Camphausen, J. Schlom, and J. W. Hodge External Beam Radiation of Tumors Alters Phenotype of Tumor Cells to Render Them Susceptible to Vaccine-Mediated T-Cell Killing Cancer Res., June 15, 2004; 64(12): 4328 - 4337. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Chikamatsu, A. Albers, J. Stanson, W. W. Kwok, E. Appella, T. L. Whiteside, and A. B. DeLeo p53110-124-specific Human CD4+ T-helper Cells Enhance in Vitro Generation and Antitumor Function of Tumor-reactive CD8+ T Cells Cancer Res., July 1, 2003; 63(13): 3675 - 3681. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |